DCF Advisers’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-107,751
| Closed | -$54.1K | – | 81 |
|
|
2024
Q4 | $54.1K | Hold |
107,751
| – | – | 0.03% | 77 |
|
|
2024
Q3 | $97.5K | Hold |
107,751
| – | – | 0.04% | 78 |
|
|
2024
Q2 | $107K | Hold |
107,751
| – | – | 0.06% | 81 |
|
|
2024
Q1 | $159K | Buy |
107,751
+13,000
| +14% | +$19.2K | 0.08% | 68 |
|
|
2023
Q4 | $103K | Buy |
94,751
+12,000
| +15% | +$13.1K | 0.06% | 65 |
|
|
2023
Q3 | $97.6K | Buy |
82,751
+67,751
| +452% | +$79.9K | 0.05% | 72 |
|
|
2023
Q2 | $21.2K | Buy |
+15,000
| New | +$21.2K | 0.01% | 75 |
|
|
2022
Q2 | – | Sell |
-53,000
| Closed | -$82K | – | 66 |
|
|
2022
Q1 | $82K | Sell |
53,000
-32,000
| -38% | -$49.5K | 0.04% | 55 |
|
|
2021
Q4 | $208K | Sell |
85,000
-2,000
| -2% | -$4.89K | 0.08% | 63 |
|
|
2021
Q3 | $219K | Buy |
87,000
+12,500
| +17% | +$31.5K | 0.1% | 66 |
|
|
2021
Q2 | $212K | Buy |
74,500
+53,500
| +255% | +$152K | 0.08% | 74 |
|
|
2021
Q1 | $49K | Buy |
+21,000
| New | +$49K | 0.02% | 81 |
|